Expanding the genetic landscape of moyamoya angiopathy: insights from 74 trios
Variant / mechanism
RNF213
De novo variants in the E3 ligase domain of RNF213, variants in known moyamoya genes and a recurrent SMAD4 gain-of-function variant (TGF-β pathway)
Summary
Trio exome sequencing was performed in 74 patients with sporadic moyamoya angiopathy, mostly of European ancestry, and an additional cohort of 200 probands was screened for recurrence. A causative variant was identified in 20 of the 74 probands (27%): six children with a severe syndromic infant-onset phenotype carried a de novo variant in the E3 ligase domain of RNF213, and fourteen carried a CNV (n = 3) or a short variant (n = 11) in a known moyamoya gene (CBL, NF1, PTPN11, DIAPH1, ANO1, JAG1, NOS3, HBB). Eleven further probands carried variants in 11 novel candidate genes, including de novo loss-of-function variants in genes regulating epigenetic modulation and RNA splicing (SETD2, HNRNPL, UBAP2L, TOP2B, PRPF40A). The gain-of-function SMAD4 p.Arg496Cys variant, de novo in one proband, recurred in the replication cohort, linking moyamoya to dysregulated TGF-β signalling. RNF213 was the only gene reaching exome-wide significance in burden testing (P = 2.11 × 10⁻¹¹).
Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.
Analysis
Outside East Asia, moyamoya turns out to be highly heterogeneous, and a 27% trio yield argues for trio exome or genome sequencing rather than RNF213 testing alone. The SMAD4 link is not entirely unexpected: SMAD4 gain-of-function variants cause Myhre syndrome, in which moyamoya had already been reported in one patient (Orphanet J Rare Dis 2022). The other eleven genes remain candidates, without functional evidence so far.
Analysis by Dr Thibaut Benquey
Why this score?
Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 7/10
Keywords
Every Wednesday · Annotated selection · Free · Unsubscribe anytime